Arcotatug Tavatecan Meets Both Co-Primary Endpoints in Later-Line CLDN18.2-Positive Gastric Cancer
Start here
An interim analysis of the phase 3 G-HOPE-001 trial, presented at ESMO 2026 as LBA77, tested arcotatug tavatecan in later-line CLDN18.2-positive gastric cancer. The drug met both co-primary endpoints of progression-free and overall survival. At the second interim analysis, median PFS was 7.1 versus 3.1 months (HR 0.45, 95% CI 0.35-0.58) and median OS was 10.2 versus 6.9 months (HR 0.57, 95% CI 0.45-0.73). Confirmed objective response rates were 37.4% versus 7.7%. The data come from an interim readout; fuller results and regulatory positioning remain open questions.
Written by a model from the reports
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comTakeda and Innovent CLDN18.2 ADC arcotatug tavatecan Phase 3 G-HOPE-001 Meets Dual PFS and OS Primary Endpoints
Takeda and Innovent Biologics announced results from the international Phase 3 G-HOPE-001 study of the CLDN18.2-targeted ADC arcotatug tavatecan. The study met both primary endpoints of progression-free survival (PFS) and overall survival (OS) in previously multiply treated patients with CLDN18.2-positive advanced gastric cancer, significantly extending survival.
- mp.weixin.qq.comPickESMO G-HOPE-001 Interim Analysis: Arcotatug Tavatecan Median PFS 7.1 Months in Later-Line CLDN18.2-Positive Gastric Cancer
The ESMO 2026 LBA77 interim analysis of the phase 3 G-HOPE-001 trial in later-line CLDN18.2-positive gastric cancer showed arcotatug tavatecan met both co-primary endpoints of PFS and OS. At IA2, median PFS was 7.1 vs 3.1 months, HR 0.45 (95% CI 0.35-0.58); median OS was 10.2 vs 6.9 months, HR 0.57 (95% CI 0.45-0.73); confirmed ORR was 37.4% vs 7.7%.
- mp.weixin.qq.comInnovent Announces at 2026 ESMO LBA That IBI343 Met PFS and OS Dual Primary Endpoints in Phase 3 G-HOPE-001 Gastric Cancer Study
At the 2026 ESMO congress, Innovent announced in a late-breaking abstract that the international multicenter phase 3 G-HOPE-001 study of the CLDN18.2 ADC IBI343 in gastric cancer met both primary endpoints of progression-free survival and overall survival.
Heat trend for this story
Heat now 1·Peak in the comparable set 10 (Oct 24 08:00)·Change over 24h in the comparable set -52%·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.